Treatments for stage 2 non–small cell lung cancer

Last medical review:

The following are treatment options for stage 2 non−small cell lung cancer. Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan.

Surgery

Surgery is a standard treatment for stage 2 non–small cell lung cancer for people who are well enough to have surgery.

A lobectomy removes the lobe of the lung where the tumour is. This is the main type of surgery for stage 2 non–small cell lung cancer. It offers the best chance that the cancer will be completely removed.

A wedge or segmental resection removes the tumour along with a margin of healthy tissue around the tumour. This type of surgery may be offered for stage 2 non–small cell lung cancer if your lung function is not very good.

A sleeve resection removes a tumour from one of the airway tubes of the lung (the bronchi) along with a margin of healthy tissue around the tumour.

An extended pulmonary resection or a chest wall resection may be done for stage 2 non–small cell lung cancer that has spread to the chest wall or other tissues around the lung.

During surgery for non–small cell lung cancer, the lymph nodes in the chest and around the lungs are removed and checked for cancer. If there is cancer in more lymph nodes than was shown with diagnostic tests, the surgery may be stopped because the cancer has spread too far for surgery to be helpful as a treatment.

You may have to have surgery again if the lab report shows that cancer is found in the margins (called positive margins) of the tissue that was removed.

Radiation therapy

External radiation therapy is offered for stage 2 non–small cell lung cancer if you are not well enough to have surgery or if you choose not to have surgery.

If you have stage 2 non–small cell lung cancer that has been completely removed with surgery, you are not offered radiation therapy after surgery. This is because research has shown that it reduces survival instead of improving it.

You may have radiation therapy after surgery if cancer is found in the margins of the tissue that was removed and you cannot have surgery again.

Stereotactic body radiotherapy (SBRT) may be offered if the cancer has not spread outside the lung.

Hypofractionated radiation treatments may be offered if you are not able to have SBRT.

3D conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) may be offered if you cannot tolerate the dose of radiation given during SBRT or hypofractionated treatments.

Chemotherapy

Chemotherapy may be offered after surgery for stage 2 non–small cell lung cancer if you are healthy enough to have chemotherapy. Research has shown it might improve survival in some people with early stage lung cancer. Your healthcare team will discuss the benefits and risks of chemotherapy with you.

The most common chemotherapy drug combination used is cisplatin and vinorelbine. If you can't have cisplatin, carboplatin and paclitaxel may be used.

Chemoradiation

Chemoradiation may be offered as a treatment if you can't have surgery and the tumour is 5 to 7 cm in size or if you have cancer that has spread to the lymph nodes. Your healthcare team will discuss the benefits and risks of chemoradiation with you.

Immunotherapy

Atezolizumab (Tecentriq) is a type of PD-L1 checkpoint inhibitor. It may be offered by itself for stage 2 non–small cell lung cancer that has been completely removed with surgery and that hasn't progressed after chemotherapy.

Clinical trials

Talk to your doctor about clinical trials open to people with non−small cell lung cancer in Canada. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.

Expert review and references

  • Stephen Lam, MD, FRCPC
  • American Cancer Society . Treating Non–Small Cell Lung Cancer . 2019 : https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell.html.
  • Cancer Care Ontario. Non-small Cell Lung Cancer Treatment Pathway Map. 2019: Version 2019.05.
  • Chiang A, Detterbeck FC, Stewart T, Decker RH, Tanoue L. Non–small cell lung cancer. DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019: 48:618–670.
  • National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (Version 3.2020) . 2020 .
  • PDQ® Adult Treatment Editorial Board . Non–Small Cell Lung Cancer Treatment (PDQ®) – Health Professional Version . Bethesda, MD : National Cancer Institute ; 2020 : https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq.
  • PDQ® Adult Treatment Editorial Board . Non–Small Cell Lung Cancer Treatment (PDQ®) – Patient Version . Bethesda, MD : National Cancer Institute ; 2020: https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society